Kither Biotech is a biopharmaceutical company developing signal transduction modulators for the treatment of rare respiratory diseases.
In recent years, Kither has focused its first-line activities on cystic fibrosis, a rare genetic disease that causes persistent lung infections and, over time, limits its sufferers’ ability to breathe. Kither has developed a small peptide as cAMP modulator, KIT2014, that the European Medicines Agency has designated as an orphan drug.
The company’s product portfolio also includes KITCL27, a small molecule PI3K inhibitor being developed as a prodrug for the treatment of Idiopathic Pulmonary Fibrosis.
(Breve testo), tincidunt non, euismod vitae, posuere imperdiet, leo. Nunc nonummy metus. Integer tincidunt. Vivamus euismod mauris. Pellentesque egestas, neque sit amet convallis pulvinar,
Kither Biotech is developing drugs that target the PI3K signalling pathway, for the treatment of rare respiratory diseases with high unmet medical needs, like cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF).